rs12153263 - CDH18
Magnitude 4.5 · 1 study on file
Reported associations
-
The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. - Journal of human genetics (2018) · Sugiura-Ogasawara M, Omae Y, Kawashima M, Toyo-Oka L, Khor SS, Sawai H, Horita T, Atsumi T, Murashima A, Fujita D, Fujita T, Morimoto S, Morishita E, Katsuragi S, Kitaori T, Katano K, Ozaki Y, Tokunaga K · PubMed 28424481
Antiphospholipid syndrome (APS) is the most important treatable cause of recurrent pregnancy loss. The live birth rate is limited to only 70-80% in patients with APS undergoing established anticoagulant therapy. Lupus anticoagulant (LA), but not anticardiolipin antibody (aCL), was found to predict adverse pregnancy outcome. Recent genome-wide association studies (GWAS) of APS focusing on aCL have shown that several molecules may be involved. This is the first GWAS for obstetric APS focusing on LA. A GWAS was performed to compare 115 Japanese patients with obstetric APS, diagnosed according to criteria of the International Congress on APS, and 419 healthy individuals. Allele or genotype frequencies were compared in a total of 426 344 single-nucleotide polymorphisms (SNPs). Imputation anal
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Obstetric antiphospholipid syndrome risk from CDH18 variant Moderate
rs12153263 T allele associated with significantly increased risk (p<0.000001)
Screening
-
Antiphospholipid antibody testing Moderate
T allele carriers have 2.6-fold increased risk of obstetric antiphospholipid syndrome
Discuss indications and timing with healthcare provider